Copyright
©The Author(s) 2021.
World J Clin Oncol. Dec 24, 2021; 12(12): 1182-1192
Published online Dec 24, 2021. doi: 10.5306/wjco.v12.i12.1182
Published online Dec 24, 2021. doi: 10.5306/wjco.v12.i12.1182
Figure 2 A schematic diagram showing cytotoxic T lymphocyte–associated antigen 4-2/B7-1-B7-2 interaction with immune cells in cancer.
CTLA-4: Cytotoxic T lymphocyte–associated antigen 4.
- Citation: Sereno M, Higuera O, Cruz Castellanos P, Falagan S, Mielgo-Rubio X, Trujillo-Reyes JC, Couñago F. Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer. World J Clin Oncol 2021; 12(12): 1182-1192
- URL: https://www.wjgnet.com/2218-4333/full/v12/i12/1182.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i12.1182